Tarsus Pharmaceuticals, Inc. (TARS)
NASDAQ:TARS
Want to see TARS full AI Analyst Report?
TARS Stock Chart & Stats
$67.24
$0.07(0.13%)
At close: 4:00 PM EST
$67.24
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)731.77K
Market Cap
$2.47B
Enterprise Value$2.54B
Total Cash (Recent Filing)$388.73M
Total Debt (Recent Filing)$88.68M
Price to Earnings (P/E)―
Beta0.15
Next Earnings
Aug 06, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding43,023,960
10 Day Avg. Volume699,285
30 Day Avg. Volume731,767
Financial Highlights & Ratios
PEG Ratio1.07
Price to Book (P/B)9.96
Price to Sales (P/S)7.58
P/FCF Ratio-153.35
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue4.75
Enterprise Value/Gross Profit5.25
Enterprise Value/Ebitda-64.99
Forecast
1Y Price Target
$95.17Price Target Upside41.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$696.32M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~90%+ product gross margins indicate very strong product-level economics for XDEMVY. High gross margins provide durable pricing power and margin expansion potential, enabling reinvestment into commercial rollout and R&D while absorbing SG&A and distribution deductions.
Robust Revenue Growth & Commercial TractionRapid top-line growth and accelerating prescriber adoption—Q1 XTENVI sales +85% YoY—signal durable commercial momentum. Increasing prescriber depth, DTC engagement gains and expanding weekly prescribing support sustainable revenue runway as market penetration improves over months.
Strengthened Commercial GovernanceAdding a proven industry CEO to the board enhances strategic commercial oversight and execution capability. Long-tenured leadership experience in scaling eye-care franchises improves probability of successful national roll-out, payer access, and disciplined commercial investment as the company scales.
Bears Say
Negative Operating & Free Cash FlowPersistent negative operating and free cash flow means the business still requires external funding to support commercial expansion and pipeline work. Although cash burn has improved, continued negative cash generation constrains financial flexibility and can pressure investment pacing or require dilution.
Ongoing Unprofitability And Negative ReturnsNegative net margins and ROE reflect that scale has not yet translated into sustainable profitability. Continued losses limit retained-capital growth and heighten reliance on external financing; until operating leverage offsets SG&A, returns to shareholders and internal reinvestment remain impaired.
Pipeline Execution & Partner DependencyKey pipeline programs (e.g., CALLIOPE TPO5) depend on partnering for Phase III scale. That creates execution and timing risk: partner selection, trial design and funding can delay clinical milestones and defer potential revenue diversification, making long-term growth partly contingent on external collaborators.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals, Inc.’s price range in the past 12 months?
Tarsus Pharmaceuticals, Inc. lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals, Inc.’s market cap?
Tarsus Pharmaceuticals, Inc.’s market cap is $2.47B.
When is Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date?
Tarsus Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Tarsus Pharmaceuticals, Inc.’s earnings last quarter?
Tarsus Pharmaceuticals, Inc. released its earnings results on May 06, 2026. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.4 by $0.24.
Is Tarsus Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Tarsus Pharmaceuticals, Inc. pay dividends?
Tarsus Pharmaceuticals, Inc. does not currently pay dividends.
What is Tarsus Pharmaceuticals, Inc.’s EPS estimate?
Tarsus Pharmaceuticals, Inc.’s EPS estimate is -0.22.
How many shares outstanding does Tarsus Pharmaceuticals, Inc. have?
Tarsus Pharmaceuticals, Inc. has 43,023,960 shares outstanding.
What happened to Tarsus Pharmaceuticals, Inc.’s price movement after its last earnings report?
Tarsus Pharmaceuticals, Inc. reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.4. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$95.17 (41.53% Upside)
$95.17 (41.53% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 245.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 17.8%
Last 30 Days ▲ 17.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
37.20%
12-Months-Change
Fundamentals
Return on Equity
-14.19%
Trailing 12-Months
Asset Growth
16.05%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted robust commercial momentum for XTENVI with a strong Q1 showing (>$145M, >85% YoY growth), growing prescriber adoption, improving DTC engagement (+~40% QoQ high-value activity), pipeline progress with two Phase II programs initiated and reiterated full-year guidance. Headwinds were largely expected and manageable: seasonal/deductible effects and weather impact in Q1, retreatment rates still progressing toward steady-state (~20%), limited near-term international royalties, and the one-time nature of a China milestone. Management emphasized continued execution, targeted commercial investments (Key Account Leaders), and confidence in achieving guidance and future growth drivers.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$95.17
▲(41.53% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.25% Insiders
21.66% Mutual Funds
51.10% Other Institutional Investors
12.38% Public Companies and
Individual Investors